Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

Moderna's trailing-12-month revenue is just ... And despite widespread outbreaks of respiratory syncytial virus (RSV), the recent approval of its RSV vaccine has also not moved the needle much.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...